Artiva 自体免疫细胞疗法试验两例死亡后停止运营
STAT+: After two deaths in autoimmune cell therapy trial, Artiva is shutting down
Artiva Biotherapeutics 周二表示，在一项针对自身免疫疾病的细胞疗法试验中两名受试者死亡后，公司正在结束运营。一名受试者在接受其 NK 细胞疗法后死于神经系统并发症，研究者判断死亡可能与细胞疗法前的化疗有关，而非细胞疗法本身；另一名受试者在治疗后约两个月猝死，研究者认为与治疗过程的任何环节无关，但死因尚未确定。
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.
Artiva Biotherapeutics said Tuesday that it’s winding down after two patients died in a trial testing its cell therapy for autoimmune diseases, the latest in a series of safety events that emerged in a promising research field.
One participant in the Phase 2 study died from a neurological complication after receiving the treatment, an NK cell therapy. Researchers, however, determined the death was likely not related to the cell therapy itself, but to a chemotherapy that was given before the cell therapy, Artiva said. It’s standard to give patients chemotherapies before infusing cell therapies to lower the patients’ white blood cell count and make room for the new cells.
A second participant experienced sudden death about two months after treatment. Researchers determined that this was not related to any component of the treatment process, but the cause of death has not been determined, the San Diego-based company said.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源：STAT News · statnews.com